Overview

PK/PD Comparison of Guanfacine ER and IR

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

Evaluate whether a 4mg/day or 6/mg day dose of extended-release guanfacine produces pharmacokinetic/dynamic (PK/PD) properties similar to 3mg/day immediate release guanfacine.

Phase:

Phase 2

Details

Lead Sponsor:

Yale University

Collaborator:

National Institute on Drug Abuse (NIDA)

Treatments:

Guanfacine